About
Johnny Page is the co-founder and CEO of Bolden Therapeutics, a preclinical biotech company developing neurogenesis-promoting therapies for neurological disease. Public bios state that he earned degrees in music, neuroscience, and biotechnology from Brown University, completed two years at Alpert Medical School, and also completed MIT I-Corps Spark entrepreneurship training. He appears publicly as an operating biotech founder rather than as a fund manager or investor.
Areas of interest
biotechnologyneuroscienceneurological diseaseneurodegenerationAlzheimer's diseaseCNS therapeuticsantisense oligonucleotidesneurogenesis